Sol-Gel Technologies Announces Reverse Share Split to Regain Nasdaq Compliance

An announcement from Sol-Gel Technologies ( (SLGL) ) is now available.

On May 1, 2025, Sol-Gel Technologies Ltd. announced a 1-for-10 reverse share split of its ordinary shares, effective May 2, 2025, to increase the per share market price and regain compliance with Nasdaq’s listing requirements. This move, approved by shareholders on April 1, 2025, will consolidate every ten shares into one, adjusting the share capital and par value accordingly, while maintaining the same percentage of ownership for shareholders.

Spark’s Take on SLGL Stock

According to Spark, TipRanks’ AI Analyst, SLGL is a Neutral.

Sol-Gel Technologies’ stock score reflects significant financial performance challenges due to negative profitability and cash flow issues. Positive technical indicators offer some short-term optimism, but the lack of valuation appeal and guidance from earnings calls creates uncertainty. Strategic financial improvements and clearer future guidance would be needed to enhance the stock’s attractiveness.

To see Spark’s full report on SLGL stock, click here.

More about Sol-Gel Technologies

Sol-Gel Technologies Ltd. is a clinical-stage dermatology company focused on developing and commercializing drug products for skin diseases. The company has developed FDA-approved treatments such as TWYNEO for acne vulgaris and EPSOLAY for rosacea. Its pipeline includes SGT-610 for Gorlin syndrome and SGT-210 for rare skin keratodermas.

YTD Price Performance: -28.08%

Average Trading Volume: 164,703

Technical Sentiment Signal: Buy

Current Market Cap: $20.34M

For a thorough assessment of SLGL stock, go to TipRanks’ Stock Analysis page.